Predicting knee replacement in participants eligible for disease-modifying osteoarthritis drug treatment with structural endpoints.


Journal

Osteoarthritis and cartilage
ISSN: 1522-9653
Titre abrégé: Osteoarthritis Cartilage
Pays: England
ID NLM: 9305697

Informations de publication

Date de publication:
06 2020
Historique:
received: 06 08 2019
revised: 17 03 2020
accepted: 26 03 2020
pubmed: 6 4 2020
medline: 20 7 2021
entrez: 6 4 2020
Statut: ppublish

Résumé

Evaluate associations between 2-year change in radiographic or quantitative magnetic resonance imaging (qMRI) structural measures, and knee replacement (KR), within a subsequent 7-year follow-up period. Participants from the Osteoarthritis Initiative were selected based on potential eligibility criteria for a disease-modifying osteoarthritis (OA) drug trial: Kellgren-Lawrence grade 2 or 3; medial minimum joint space width (mJSW) ≥2.5 mm; knee pain at worst 4-9 in the past 30 days on an 11-point scale, or 0-3 if medication was taken for joint pain; and availability of structural measures over 2 years. Mean 2-year change in structural measures was estimated and compared with two-sample independent t-tests for KR and no KR. Area under the receiver operating characteristic curve (AUC) was estimated using 2-year change in structural measures for prediction of future KR outcomes. Among 627 participants, 107 knees underwent KR during a median follow-up of 6.7 years after the 2-year imaging period. Knees that received KR during follow-up had a greater mean loss of cartilage thickness in the total femorotibial joint and medial femorotibial compartment on qMRI, as well as decline in medial fixed joint space width on radiographs, compared with knees that did not receive KR. These imaging measures had similar, although modest discrimination for future KR (AUC 0.62, 0.60, and 0.61, respectively). 2-year changes in qMRI femorotibial cartilage thickness and radiographic JSW measures had similar ability to discriminate future KR in participants with knee OA, suggesting that these measures are comparable biomarkers/surrogate endpoints of structural progression.

Identifiants

pubmed: 32247871
pii: S1063-4584(20)30963-8
doi: 10.1016/j.joca.2020.03.012
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

782-791

Informations de copyright

Copyright © 2020 Osteoarthritis Research Society International. All rights reserved.

Auteurs

C K Kwoh (CK)

University of Arizona Arthritis Center, University of Arizona College of Medicine, Tucson, AZ, USA. Electronic address: kwoh@arthritis.arizona.edu.

H Guehring (H)

Merck KGaA, Darmstadt, Germany. Electronic address: hans.guehring@merckgroup.com.

A Aydemir (A)

EMD Serono Global Clinical Development Center, Billerica, MA, USA. Electronic address: aida.aydemir@emdserono.com.

M J Hannon (MJ)

University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: michaeljhannon@gmail.com.

F Eckstein (F)

Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria; Chondrometrics GmbH, Ainring, Germany. Electronic address: felix.eckstein@pmu.ac.at.

M C Hochberg (MC)

University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mhochber@som.umaryland.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH